NIOSHTIC-2 Publications Search
Pharmaceutical considerations in the use of tetrandrine to treat silicosis.
Ma-JK; Chao-H; Ma-JY; Hubbs-A; Castranova-V
Silica and silica-induced lung diseases. Castranova V, Vallyathan V, Wallace WE, eds. Boca Raton, FL: CRC Press, 1995 Dec; :331-341
This chapter reviewed the disadvantages of conventional oral tetrandrine (518343) therapy in the treatment of silicosis and considered the pharmaceutical strategy for improved therapeutic effects of tetrandrine. This strategy included use of multiple emulsions as a drug delivery system, tetrandrine emulsion, the effect of emulsin on drug cell interactions, the effect of tetrandrine on the oxygen consumption of alveolar macrophages (AM) at rest and in response to zymosan stimulation following 1 hour incubation, and the emulsion mediated tetrandrine activity in-vivo. Studies suggested that tetrandrine effectively inhibits the macrophage orchestrated inflammatory process in response to silica (14808607) exposure and the subsequent fibrotic development. Data indicated that tetrandrine protects lung cells from silica toxicity and stimulation and restores healthy AM populations even after the drug has been eliminated from the pulmonary region. Tetrandrine water/oil/water emulsion was consistently more efficacious than the solution dosage form in the treatment of silica induced granulomatous pneumonia and alveolar lipoproteinosis in rats. Studies have demonstrated that early drug treatment following silica exposure may delay the fibrotic process by inhibiting abnormal cellular activity prior to the fibrotic event and restoring normal cell functions, thus allowing time for the lung to clear its dust problem. A delay or inhibition of the fibrotic process may have a very significant effect on development of the disease.
NIOSH-Author; NIOSH-Cooperative-Agreement; Pulmonary-system-disorders; Medical-treatment; Lung-irritants; Lung-disease; Respiratory-system-disorders; Silica-dusts; Silicosis; Lung-cells; Laboratory-animals
Castranova-V; Vallyathan-V; Wallace-WE
Cooperative Agreement; Grant
Silica and silica-induced lung diseases
Center to Protect Workers' Rights
Page last reviewed: September 2, 2020
Content source: National Institute for Occupational Safety and Health Education and Information Division